RE: interesting read13 Mar 2023 16:32
https://www.annualreports.com/HostedData/AnnualReportArchive/s/NASDAQ_SRRA_2020.pdf
thanks sadoldgit and hotblackdesiato i was was looking for the old trademark names that sierra logged as lost everything on old computer found this bit in there old report page 12
We have exclusively licensed CPF’s rights to patents owned by Cancer Research Technology (CPF), a subsidiary of Cancer Research UK (CRUK), directed
to compositions of matter and methods of use related to SRA737 and other Chk1 inhibitors. As of December 31, 2020, these rights included two issued
U.S. patents and two pending U.S. patent application comprising claims directed to compositions of SRA737 and methods of using SRA737 for the
treatment of cancer indications as a single agent, or in combination with a DNA damaging agent. The two issued U.S. patents and any patents issuing from
the pending U.S. utility application are expected to expire in 2033, absent any adjustments or extensions. As of December 31, 2020, these rights also
included 27 issued foreign patents and 6 pending foreign patent applications in 27 foreign jurisdictions, including Australia, Canada, China, Europe and
Japan comprising claims directed to compositions of SRA737 and methods of using SRA737 for the treatment of cancer indications as a single agent, or in
combination with a DNA damaging agent. These foreign patents, and any patents issuing from these pending foreign patent applications, are expected to
expire in 2033, absent any extensions. As of December 31, 2020, these rights also included, one pending U.S. application and 4 pending foreign
applications comprising claims directed to biomarkers and patient selection when using SRA737 to treat cancer indications. Any patents issuing from these
pending patent applications are expected to expire in 2038, absent any adjustments or extensions. As of December 31, 2020, these rights also included one
pending U.S. application and 8 pending foreign applications comprising claims directed to methods of using SRA737 in combination with PARP inhibitors
for inhibiting tumor reduction. Any patents issuing from these pending patent applications are expected to expire in 2038, absent any adjustments or
extensions. As of December 31, 2020, these rights also included one pending U.S. application and 7 pending foreign applications comprising claims
directed to methods of using SRA737 as a monotherapy or in combination therapy to treat cancer indications. Any patents issuing from these pending
patent applications are expected to expire in 2039, absent any adjustments or extensions. As of December 31, 2020, these rights also included one pending
Patent Cooperation Treaty application filed by the Company and The University of Texas M.D. Anderson Cancer Center comprising claims directed to
methods of using SRA737 to treat cancer indications. Additionally, as of December 31, 2020, these rights also included one pending Patent Cooperation
Treaty application compri
Sign In
Follow the stocks
